Starpharma share price charges higher on positive trial results

The Starpharma Holdings Limited (ASX:SPL) share price is charging higher on Tuesday after the release of positive trial results…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is charging higher on Tuesday morning.

At the time of writing the dendrimer products developer's shares are up 7% to $1.31.

Why is the Starpharma share price charging higher?

This morning Starpharma announced the successful completion of the phase 1 component of its phase 1/2 trial for DEP cabazitaxel.

DEP cabazitaxel is a patented, detergent free, nanoparticle version of the cancer drug, Jevtana.

Jevtana is a leading oncology agent used to treat advanced prostate cancer and is also under development for other cancers including testicular, ovarian, breast, and head and neck.

According to today's release, the phase 1 trial of DEP cabazitaxel met its objective of evaluating safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose.

The trial enrolled 14 patients with a range of cancers, including prostate, ovarian, cholangiocarcinoma and pancreatic cancer. Efficacy signals were observed in 67% of evaluable patients and included prolonged stable disease (>47 weeks) and significant reductions in specific tumour biomarkers such as prostate specific antigen.

The release advises that these efficacy signals are particularly encouraging given all patients in the study were heavily pre-treated and had either progressed or had stopped responding to prior anti-cancer therapies to qualify for entry into the DEP cabazitaxel study.

Management advised that the trial will now transition seamlessly into phase 2, with two new sites initiated and recruitment activities already underway.

Starpharma CEO, Dr Jackie Fairley, said, "We're pleased to advance our second DEP product to phase 2, and are very excited to see the promising efficacy signals observed in such a resistant patient cohort, and the remarkably low incidence of adverse events, including bone-marrow toxicity/neutropenia, with DEP cabazitaxel. We look forward to sharing these results with commercial partners."

DEP cabazitaxel has the potential to be a lucrative product for Starpharma. It estimates that Jevtana sales will exceed US$500 million this year.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Green stock market graph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was one for the history books today.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Boss Energy, DroneShield, Pilbara Minerals, and Polynovo shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous, but positive, Tuesday for ASX investors.

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Share Gainers

Why Bapcor, Ramelius, Sandfire, and WIA Gold shares are rising today

These shares are having a better day than most on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors started the week off in a good mood today.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Bellevue Gold, Bubs, Clarity Pharmaceuticals, and Regal Partners shares are rising today

These shares are starting the week on a positive note.

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Travel Shares

Guess which ASX All Ords travel stock just rocketed 17% on an earnings upgrade

Investors are piling into the ASX All Ords travel stock today. Here's what's happening.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »